期刊
ONCOTARGET
卷 8, 期 41, 页码 71164-71172出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.17029
关键词
colorectal cancer; cost-effectiveness; cetuximab; gene mutation
资金
- Shanghai Municipal Commission of Health and Family Planning [15GWZK0901, 2012ZDXK003]
PURPOSE: To test the cost-effectiveness of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment in patients with metastatic colorectal cancer (mCRC) from a Chinese medical insurance perspective. RESULTS: Baseline analysis showed that the addition of cetuximab increased quality-adjusted life-years (QALYs) by 0.63, an increase of $17,086 relative to FOLFIRI chemotherapy, resulting in an incremental cost-effectiveness ratio (ICER) of $27,145/QALY. When the patient assistance program (PAP) was available, the ICER decreased to $14,049/QALY, which indicated that the cetuximab is cost-effective at a willingness-to-pay threshold of China ($22,200/QALY). One-way sensitivity analyses showed that the median overall survival time for the cetuximab was the most influential parameter. METHODS: A Markov model by incorporating clinical, utility and cost data was developed to evaluate the economic outcome of cetuximab in mCRC. The lifetime horizon was used, and sensitivity analyses were carried out to test the robustness of the model results. The impact of PAP was also evaluated in scenario analyses. CONCLUSIONS: RAS testing with cetuximab treatment is likely to be cost-effective for patients with mCRC when PAP is available in China.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据